Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?
Investors focused on the Medical space have likely heard of Integer Holdings (ITGR), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of ITGR and the rest of the Medical group's stocks.
Integer Holdings is one of 757 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ITGR is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ITGR's full-year earnings has moved 5.94% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ITGR has moved about 59.27% on a year-to-date basis. In comparison, Medical companies have returned an average of 5.49%. This means that Integer Holdings is outperforming the sector as a whole this year.
Looking more specifically, ITGR belongs to the Medical - Instruments industry, which includes 88 individual stocks and currently sits at #163 in the Zacks Industry Rank. Stocks in this group have lost about 10.06% so far this year, so ITGR is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track ITGR. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integer Holdings Corporation (ITGR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
